Peptidyl Argenine Deiminase- 4 (PADI4) as Diagnostic and Prognostic Marker in Rheumatoid Arthritis

Abstract

Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint destruction, functional impairment, disability, and reduced life expectancy. The bone and cartilage destruction rarely heals, the damage accumulates over time, thus early interfering with the inflammatory cascade before it is fully established is most effective. Aim of the Work: His study is designed to assess the role of serum PADI4 level as diagnostic and prognostic marker in RA patients. Patients and Methods: This study was conducted on 31 RA patients diagnosed according to the American College of Rheumatology (ACR) new classification criteria. Ten healthy individuals matched for age and sex who served as a control group. In conclusion, our study highlighted that PAD4 sensitivity was 90.3% and specificity was 100% while anti-CCP sensitivity was 93% and its specificity was 100%. According to these findings serum PAD4 provide additional diagnostic value not over the already established anti-CCP, but it is correlated with disease activity and can be used in follow up remission in RA patients.